Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 5.5% – Here’s Why

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) shares dropped 5.5% during mid-day trading on Thursday . The company traded as low as $1.3601 and last traded at $1.37. Approximately 71,574 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 4,501,084 shares. The stock had previously closed at $1.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, Cyclerion Therapeutics presently has an average rating of “Sell”.

Cyclerion Therapeutics Stock Down 5.5%

The firm has a 50-day moving average of $1.50 and a two-hundred day moving average of $2.07. The company has a market capitalization of $5.38 million, a PE ratio of -1.83 and a beta of 0.96.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.30) EPS for the quarter. The business had revenue of $0.88 million during the quarter. Cyclerion Therapeutics had a negative net margin of 77.02% and a negative return on equity of 24.61%.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.